$2.1B Endocyte Deal a Record-Breaker

Posted: Updated:
(Image courtesy of Endocyte) (Image courtesy of Endocyte)
WEST LAFAYETTE -

A veteran of Indiana's life sciences industry says the proposed blockbuster sale of West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) is good for the ecosystem in the state. Switzerland-based Novartis AG has signed an agreement to acquire Endocyte for $2.1 billion, which BioCrossroads Project Director Brian Stemme says is "by far" the largest-ever acquisition of an Indiana life sciences company. The deal still faces regulatory and shareholder hurdles.

In an interview with Inside INdiana Business, Stemme said the deal is validation of more than 20 years of support and determination. The company was born in the mid-1990s from biotechnology developed at Purdue University by eventual founder Philip Low and fellow biochemist Christopher Leamon. Low serves as chief science officer and Leamon is vice president of research and development.

"There's been just a lot of people between Dr. Low, Purdue University, the state of Indiana, all the executives and scientists that have been supporting that company over the years, so to see it really be recognized and work with a company that can help get that product to market, it's exciting," Stemme said. "It's a validation that all those folks knew what they were doing, knew what they were talking about, they saw the promise of that technology early and then just kept on grinding."

Stemme says the deal adds to some $8 billion in transactions involving Hoosier life sciences businesses in the last five years, including:

Endocyte is based at Purdue Research Park in West Lafayette, and last month, it was recognized as the first Purdue startup to be valued at $1.5 billion. Purdue President Mitch Daniels says "the sale of Endocyte is a landmark moment, but given the explosion in entrepreneurship and new start-ups at Purdue, I'm sure it's the first of many to come. "We are so deeply proud of our Purdue scientists whose genius is saving lives from cancer, and now has brought great new wealth to Indiana."

Last year, the company acquired a promising prostate cancer therapy in the late stages of development from ABX GmbH in Germany. Endocyte says it expects the acquisition will boost the chances of PSMA-617 going to market. Endocyte went public in 2011, raising $79 million during its initial public offering.

BioCrossroads Project Director Brian Stemme said the deal is validation of more than 20 years of support and determination.
  • Perspectives

    • Regional Investment Proposal Could be a Game Changer for Quality of Place Initiatives in Indiana

      While quality of place may be defined differently by people, a growing number of Hoosiers recognize the importance of this issue. In particular, the impact of quality of place on talent attraction and retention in a geographic area cannot be ignored. The future of every community is dependent on quality of place. Like many Midwestern states, Indiana is not growing at the same pace as areas in the southern and western regions of the United States.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • The Vogue opened as a movie house in 1938, then reopened as a nightclub in 1977. (Picture Courtesy: The Vogue)

      Tech Vets Purchase Popular Indy Nightclub

      A group of Indianapolis tech entrepreneurs has bought a popular nightclub in the city's Broad Ripple neighborhood. High Alpha co-founder Eric Tobias and former MOBI executives Scott Kraege and Andrew Davis say they will retain the Vogue's current staff to manage the venue's day-to-day operations. The new owners say they will detail plans to reinvigorate the Vogue through enhanced fan experience and engagement in the coming months. Tobias, Kraege and Davis purchased the Vogue...

    • (Image courtesy of the Indianapolis Colts.)

      Colts Announce 2019 Regular Season Schedule

      The 2019 NFL schedule is out and the Indianapolis Colts will play in several high-profile games. All three of the Colts’ 2019 primetime games will be on the road against defending division champions. 

    • Bryan Brenner is the CEO of FirstPerson and a founding partner of Performance Lab.

      FirstPerson Execs Launch Performance Lab

      A new firm founded by executives from Indianapolis-based FirstPerson says it wants to help companies strengthen performance. Performance Lab uses a field test known as the Performance Climate Survey, which provides insights into a company’s performance culture. Founding Partner Bryan Brenner, who is also the CEO of FirstPerson, says the firm has already landed a number of early customers, including Goodwill Industries, the Indy Chamber and the Central Indiana Community Foundation.

    • Skilled Nursing Facility Proposed for Merrillville

      A new $7 million skilled nursing facility is being proposed in Merrillville. Our partners at The Times of Northwest Indiana report the development would include five residential buildings outfitted with 12 beds, a dining area, beauty salon and spa. 

    • 2019 'Stellar' Finalists Announced

      Lieutenant Governor Suzanne Crouch has unveiled the finalists for the 2019 Stellar Communities Program. The four regions selected will receive a planning grant and work with the Indiana Communities Institute at Ball State University on project alignment and continued planning efforts. Stellar Communities, launched in 2011, is led by the Indiana Office of Community and Rural Affairs and aims to boost community and economic development and promote local and regional partnerships.